Analysed ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) News Sources
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
18-02-2026
yahoo.com
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
06-03-2026
yahoo.com
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31-03-2026
yahoo.com
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
21-04-2026
yahoo.com
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
27-04-2026
yahoo.com
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
05-05-2026
yahoo.com
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
08-05-2026
yahoo.com
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
15-05-2026
yahoo.com
What is the current price of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The current price of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is $1.73.
ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) since the previous trading day is $0.045.
ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) since the previous trading day is 2.6706%.
What is the most recent average sentiment score for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The most recent average sentiment score for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The most recent sentiment for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is .
SEC-8K** Filing Available For ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.